The chemotherapy pralatrexate and the antibiotic azithromycin were successful at preventing replication of the SARS-CoV-2 virus, according to research with Shenzhen Institutes of Advanced Technology in China.

South San Francisco-based Freenome closed on an oversubscribed $270 million Series C financing, with the round led by new investor Bain Capital Life Sciences and existing investor Perceptive Advisors.

Routine medical tests critical for detecting and monitoring cancer and other conditions plummeted in the United States since mid-March, as the coronavirus spread and public officials urged residents to stay home, according to a new report by Komodo Health.

Exact Sciences Corp.’s shares shot up as much as 26 percent after announcing that Pfizer Inc. would share marketing expenses and co-promote the company’s stool screening test for colorectal cancer.

As many as 270 women in England may have died prematurely of breast cancer because of an IT failure that led to 450,000 patients missing out on routine screening appointments.

 

Charles River Laboratories, a contract research organization (CRO) with headquarters in Wilmington, Mass., is buying MPI Research for about $800 million.

An influential physician task force backed by the U.S. government is softening its opposition to routine prostate cancer screening.

(Reuters Health) – U.S. public health funding – which covers things like disease prevention, cancer screenings, contraceptives and vaccines – has been steadily falling in recent years and is expected to keep going down, a recent study projects. Real, inflation-adjusted public health expenditures surged from $39 per capita in 1960 to $281 per capita in […]

(Reuters Health) – In a major shift, the American Cancer Society is recommending that women at average risk of breast cancer get annual mammograms starting at age 45 rather than at age 40, and that women 55 and older scale back screening to every other year. The new guidelines, published on Tuesday in JAMA, fall […]

Men with early-stage prostate cancer are increasingly opting for regular monitoring and holding off on treatment unless the disease progresses, a new study suggests. Use of so-called active surveillance, or watchful waiting, among men with localized prostate cancer was low from 1990 through 2009 but rose sharply between 2010 and 2013, according to data published […]